| Literature DB >> 35784708 |
Guang Yang1, Wenqing Xie1, Yilan Ding2, Weiyang Wang2, Cheng Huang3, Tingxiao Zhao4, Yusheng Li1,5.
Abstract
Background: Tetrandrine has been the focus of many studies in recent years. Currently, no bibliometric study in this field has been published. This study presents a bibliometric analysis of the articles on tetrandrine research from the WOS core database during the recent two decades.Entities:
Keywords: RStudio; VOSviewer; arthritis; bibliometric; cancer; pharmacokinetics; tetrandrine
Year: 2022 PMID: 35784708 PMCID: PMC9240465 DOI: 10.3389/fphar.2022.896050
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Flow diagram of the search strategy.
Types of retrieved documents (2000–2021).
| Document type | Total publications (TP) | Percentage (%) |
|---|---|---|
| Article | 425 | 86.73 |
| Meeting abstract | 42 | 8.57 |
| Review | 9 | 1.84 |
| Correction | 7 | 1.43 |
| Editorial material | 3 | 0.61 |
| Proceedings paper | 2 | 0.41 |
| Letter | 1 | 0.20 |
| Retraction | 1 | 0.20 |
| Total | 490 | 100.00 |
Annual scientific productions and citations.
| Year | Actual value | Normalized value | ||||
|---|---|---|---|---|---|---|
| Articles | Average citation | Citations | Articles | Average citations | Citations | |
| 2000 | 9 | 32 | 287 | 0.00 | 0.71 | 0.34 |
| 2001 | 13 | 20 | 263 | 0.12 | 0.45 | 0.31 |
| 2002 | 19 | 43 | 820 | 0.30 | 0.96 | 1.00 |
| 2003 | 9 | 31 | 283 | 0.00 | 0.70 | 0.33 |
| 2004 | 15 | 45 | 671 | 0.18 | 1.00 | 0.81 |
| 2005 | 10 | 17 | 165 | 0.03 | 0.36 | 0.19 |
| 2006 | 10 | 32 | 319 | 0.03 | 0.71 | 0.38 |
| 2007 | 16 | 28 | 452 | 0.21 | 0.63 | 0.54 |
| 2008 | 16 | 28 | 443 | 0.21 | 0.61 | 0.53 |
| 2009 | 20 | 22 | 432 | 0.33 | 0.48 | 0.52 |
| 2010 | 18 | 27 | 492 | 0.27 | 0.61 | 0.59 |
| 2011 | 30 | 27 | 819 | 0.64 | 0.61 | 1.00 |
| 2012 | 12 | 27 | 326 | 0.09 | 0.60 | 0.39 |
| 2013 | 23 | 30 | 688 | 0.42 | 0.67 | 0.84 |
| 2014 | 24 | 23 | 542 | 0.45 | 0.50 | 0.65 |
| 2015 | 26 | 20 | 512 | 0.52 | 0.43 | 0.62 |
| 2016 | 39 | 19 | 741 | 0.91 | 0.42 | 0.90 |
| 2017 | 35 | 15 | 526 | 0.79 | 0.33 | 0.63 |
| 2018 | 33 | 13 | 426 | 0.73 | 0.28 | 0.51 |
| 2019 | 37 | 13 | 492 | 0.85 | 0.29 | 0.59 |
| 2020 | 42 | 4 | 180 | 1.00 | 0.09 | 0.20 |
| 2021 | 32 | 0 | 15 | 0.70 | 0.00 | 0.00 |
FIGURE 2Matrix scatter diagram.
Top 10 authors distributed by publications and citations.
| Rank | Author | Publications | Country | Institution | First author | DF | DF rank | Author | Country | Institution | H-Index | G-Index | M-index | TC | Publications | PY_start |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zhang,H | 19 | China | Jinan Univ, Affiliated Hosp 1 | 4 | 0.21 | 7 | Li WH | China | Wuhan Univ | 11 | 11 | 0.92 | 547 | 12 | 2011 |
| 2 | Hirano,T | 14 | Japan | Tokyo Univ | 5 | 0.36 | 4 | Liu X | China | Wuhan Univ | 7 | 8 | 0.58 | 396 | 8 | 2011 |
| 3 | Wang,J | 14 | China | Southeast Univ, ZhoDa Hosp | 3 | 0.21 | 5 | Liu T | China | Wuhan Univ | 9 | 9 | 0.90 | 380 | 9 | 2013 |
| 4 | Zhang,Y | 14 | China | Jinan Univ | 3 | 0.21 | 6 | Chen Y | China | Natl Taiwan Univ Hosp | 8 | 10 | 0.57 | 353 | 11 | 2009 |
| 5 | Koul,S | 13 | America | Univ Colorado | 7 | 0.54 | 3 | Fu LW | China | Sun Yat Sen Univ | 3 | 3 | 0.14 | 322 | 3 | 2002 |
| 6 | Li,WH | 12 | China | Wuhan Univ | 0 | 0.00 | 9 | Liang YJ | China | Sun Yat Sen Univ | 3 | 3 | 0.14 | 322 | 3 | 2002 |
| 7 | Chen,Y | 11 | China | Natl Taiwan Univ Hosp | 8 | 0.73 | 1 | Pan QC | China | Sun Yat Sen Univ | 2 | 2 | 0.10 | 272 | 2 | 2002 |
| 8 | Chen,J | 10 | China | Huazhong Univ | 2 | 0.20 | 8 | Yang XP | China | Sun Yat Sen Univ | 2 | 2 | 0.10 | 272 | 2 | 2002 |
| 9 | Chen,BA | 9 | China | Southeast Univ | 6 | 0.67 | 2 | Gong K | China | Wuhan Univ | 3 | 3 | 0.25 | 266 | 3 | 2011 |
| 10 | Koul,HK | 9 | America | Univ Colorado | 0 | 0.00 | 10 | Tseng SH | China | Taiwan Univ Hosp | 8 | 9 | 0.57 | 259 | 9 | 2009 |
PY_Start: the year that researcher published his first article during the investigated period.
FIGURE 3Network visualization map of co-authorship in TET research.
Top 10 Country distributed by publications and citations.
| Rank by publications | Country | Articles | Citations | Average citations (AC) | Percentage (%) | SCP | MCP | Rank by AC |
|---|---|---|---|---|---|---|---|---|
| 1 | China | 362 | 6398 | 17.67 | 80.09 | 332 | 30 | 6 |
| 2 | United States | 19 | 473 | 24.89 | 4.20 | 11 | 8 | 4 |
| 3 | South Korea | 18 | 577 | 32.06 | 3.98 | 14 | 4 | 1 |
| 4 | Japan | 15 | 174 | 11.6 | 3.32 | 7 | 8 | 7 |
| 5 | Canada | 6 | 120 | 20 | 1.33 | 4 | 2 | 5 |
| 6 | Germany | 5 | 135 | 27 | 1.11 | 2 | 3 | 3 |
| 7 | India | 5 | 155 | 31 | 1.11 | 5 | 0 | 2 |
| 8 | Mexico | 5 | 38 | 7.6 | 1.11 | 4 | 1 | 8 |
| 9 | France | 3 | 0 | 0 | 0.66 | 0 | 3 | 9 |
| 10 | Chile | 2 | 0 | 0 | 0.44 | 0 | 2 | 10 |
SCP, single country publications; MCP, multiple country publications.
FIGURE 4Publication distributed by single country publications and multiple country publications.
FIGURE 5Network visualization map of international collaboration among countries. The thickness of the connecting line between any two countries indicates the strength of collaboration. Countries with similar colors form one cluster.
Keywords distributed by frequency.
| Rank | Author keywords (DE) | Frequency | Keywords-plus (ID) | Frequency |
|---|---|---|---|---|
| 1 | Tetrandrine | 326 | Apoptosis | 86 |
| 2 | Apoptosis | 68 |
| 68 |
| 3 | Autophagy | 21 | Expression | 67 |
| 4 | Fangchinoline | 17 | Activation | 59 |
| 5 | NF-Kappa B | 16 | Cells | 50 |
| 6 | Multidrug resistance | 15 | Multidrug-Resistance | 50 |
| 7 | P-Glycoprotein | 14 | Inhibition | 46 |
| 8 | Pharmacokinetics | 14 | Mechanisms | 41 |
| 9 | Proliferation | 13 | Cancer | 35 |
| 10 | Tetrandrine (TET) | 10 | Growth | 34 |
FIGURE 6Network visualization map of the author keywords. keywords with similar colors form one cluster.
FIGURE 7Top 10 keywords with the strongest citation bursts.
Top 10 journals distributed by publications and citations.
| Rank | Journal | Publications | % Of 482 | IF(JCR 2020) | JIF quartile | Journal | Total citations | Publications | Average citations (AC) | H-Index | IF(JCR 2020) | JIF quartile | AC rank |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Acta pharmacol sin | 21 | 4.36 | 6.15 | Q1 | Acta pharmacol sin | 651 | 21 | 31 | 14 | 6.15 | Q1 | 10 |
| 2 | Eur J. pharmacol | 8 | 1.66 | 4.43 | Q2 | Cancer chemoth pharm | 280 | 4 | 70 | 4 | 3.33 | Q3 | 2 |
| 3 | Int J. oncol | 8 | 1.66 | 5.65 | Q2 | Int J. oncol | 272 | 8 | 34 | 8 | 5.65 | Q2 | 9 |
| 4 | Cancer res | 7 | 1.45 | 12.70 | Q1 | Biochem pharmacol | 234 | 5 | 47 | 5 | 12.70 | Q1 | 7 |
| 5 | Oncol rep | 7 | 1.45 | 3.91 | Q3 | Mol pharmaceut | 234 | 4 | 59 | 4 | 3.91 | Q3 | 4 |
| 6 | Biochem bioph res Co. | 6 | 1.24 | 3.58 | Q3 | Mol pharmacol | 227 | 3 | 76 | 3 | 3.58 | Q3 | 1 |
| 7 | Blood | 6 | 1.24 | 23.63 | Q1 | Cancer lett | 190 | 4 | 48 | 4 | 8.68 | Q1 | 5 |
| 8 | Drug des dev ther | 6 | 1.24 | 4.16 | Q2 | J. ethnopharmacol | 188 | 4 | 47 | 4 | 4.36 | Q2 | 6 |
| 9 | Evid-based compl alt | 6 | 1.24 | 2.63 | Q2 | Int J. cancer | 183 | 3 | 61 | 2 | 7.40 | Q1 | 3 |
| 10 | Faseb J. | 6 | 1.24 | 5.19 | Q2 | Life sci | 181 | 4 | 45 | 4 | 5.04 | Q2 | 8 |
FIGURE 8Visualization of Top 10 prolific journals publications distribution according to the temporal order. Publications with less than 2 are presented in the form of black dot. Publications with more than 2 are represented in number form.
Top 10 cited literatures.
| Rank | Authors | Citations | Article title | Journal abbreviation | Date | Volume | Doi | Pubmed id |
|---|---|---|---|---|---|---|---|---|
| 1 | Fu LW | 160 | The multidrug resistance of tumour cells was reversed by tetrandrine | Eur J. cancer | 2002 | 38 | 10.1016/S0959-8,049 (01)00356-2 | 11818209 |
| 2 | Fu LW | 146 | Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance | Cancer chemoth pharm | 2004 | 53 | 10.1007/s00280-003-0742-5 | 14666379 |
| 3 | He BC | 128 | Tetrandrine Inhibits Wnt/beta-catenin signaling and suppresses tumor growth of human colorectal cancer | Mol pharmacol | 2011 | 79 | 10.1124/mol.110.068668 | 20978119 |
| 4 | Pang ZQ | 116 | Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats | Mol pharmaceut | 2010 | 7 | 10.1021/mp100277h | 20957995 |
| 5 | Kim DE | 114 | Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human lung cells | Biomolecules | 2019 | 9 | 10.3390/biom9110696 | 31690059 |
| 6 | Liu CY | 111 | Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma | Int J. Cancer | 2011 | 129 | 10.1002/ijc.25817 | 21128229 |
| 7 | Bhagya N | 109 | Tetrandrine—A molecule of wide bioactivity | Phytochemistry | 2016 | 125 | 10.1016/j.phytochem. 2016.02.005 | 26899361 |
| 8 | Gong K | 103 | Autophagy-related Gene 7 (ATG7) and Reactive Oxygen Species/extracellular signal-regulated kinase regulate Tetrandrine-induced autophagy in human hepatocellular carcinoma | J. Biol Chem | 2012 | 287 | 10.1074/jbc.M112.370585 | 22927446 |
| 9 | Wang G | 102 | Herbal alkaloid tetrandrine: from an ion channel blocker to inhibitor of tumor proliferation | Trends Pharmacol Sci | 2004 | 25 | 10.1016/j.tips. 2004.01.009 | 15058281 |
| 10 | Meng LH | 101 | Tetrandrine induces early G (1) arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G (1)-S-specific cyclin-dependent kinases and by inducing p53 and p21(Cip1) | Cancer Res | 2004 | 64 | 10.1158/0008-5472.CAN-04-0313 | 15604277 |
FIGURE 9The top 10 most productive institutions. The data in the figure refer to the publication of the specific institution. The size of each board area is proportional to the number of articles.
FIGURE 10Network visualization of institutions collaboration.